Shilpa Medicare Limited Business Intelligence Report
Shilpa Medicare Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
No quarterly summary available yet.
AI Summary
Shilpa Medicare is a specialized pharmaceutical player with a strong foothold in the oncology API and formulation segments. Over the last decade, the company has transitioned from a pure-play API manufacturer to a vertically integrated player with expanding capabilities in biologics and novel drug delivery systems. While revenue growth has been steady at an 8% 10-year CAGR, profitability has faced significant headwinds due to heavy R&D spending and regulatory inspections at key facilities. Recent performance shows a sharp recovery, with trailing twelve-month (TTM) profit growth exceeding 165%…
Key Changes in FY2026
The company has evolved from a pure-play oncology API manufacturer into a vertically integrated specialty pharmaceutical player. Over the last decade, it has expanded from 19 API blocks to include sophisticated formulation facilities for injectables and oral disintegrating films. The strategic pivot towards Biologics and high-entry-barrier products like the Gate2Brain acquisition indicates a move up the value chain. Geographic expansion has been successful, with facilities now holding approvals from USFDA, PMDA Japan, and TGA Australia. Despite stagnation in sales growth between 2017-2021, the recent surge in TTM sales suggests the fruition of long-term R&D and capacity expansion.
Management Commentary
Management demonstrates deep technical expertise in oncology and regulated markets, evidenced by their successful USFDA, EU, and PMDA approvals. Vision is commendable, particularly the early entry into biologics, but execution from a financial discipline standpoint has been lacking. Transparency is moderate; while con-call frequency is high, clarity on the path to debt reduction has been historically vague. There is a clear effort to move up the value chain, but the high management remuneration relative to recent depressed profits raises minor alignment questions. The strategic impact of recent facility approvals suggests management is navigating regulatory hurdles effectively.
Financial Highlights
The financial profile is characterized by moderate revenue growth (11% 5-year CAGR) but highly volatile margins. Operating margins collapsed from 24% in FY20 to a low of 9% in FY23 before rebounding toward 21% in FY24. High interest costs, which peaked at nearly ₹92 Cr in FY24, have significantly eaten into the bottom line, resulting in a net loss in FY23. Return on Capital Employed (ROCE) has historically been weak, currently sitting at 11%, well below its 18% peak in 2015. Growth quality is deemed 'average' as it has been fueled by heavy borrowing rather than internal accruals.
Major Opportunities
- Leading API manufacturer in Oncology niche
- Strong historical presence in regulated markets
- Robust revenue growth in TTM (20%)
Major Risks
- Persistently negative Free Cash Flow for 10 years
- Constant equity dilution (Equity capital up)
- High inventory days (291-427 range)
About Shilpa Medicare Limited's Annual Report & Financial Performance
The latest Shilpa Medicare Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Shilpa Medicare Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Shilpa Medicare Limited — Frequently Asked Questions
Explore more Shilpa Medicare Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.